Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.

Also called NCT03032965

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 131 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03032965
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03032965. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-07 (actual). Results posted on 2017-12-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
Intervention (Drug)
Adenosine
Intervention (Drug)
Isoproterenol
Lead sponsor
University of Michigan (class: other)

Record details

Record id
cardio:ct-nct03032965
Content hash
f7f4f3a60eb214a84344032984c06b0e85e3b005f7b22b8df84c62ff1d90d72d